Susan D. Wyrick - 06 Mar 2025 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
Acting Chief Financial Officer and Principal Accounting Officer
Signature
/s/ Bernard J. Cassidy, Attorney-in-Fact for Susan D. Wyrick
Issuer symbol
SANA
Transactions as of
06 Mar 2025
Net transactions value
-$2,140
Form type
4
Filing time
10 Mar 2025, 20:13:08 UTC
Previous filing
03 Mar 2025
Next filing
16 Dec 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SANA Common Stock Options Exercise $0 +3,250 +2.1% $0.000000 158,231 07 Mar 2025 Direct
transaction SANA Common Stock Tax liability $2,140 -836 -0.53% $2.56 157,395 10 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SANA Restricted Stock Units Award $0 +41,667 $0.000000 41,667 06 Mar 2025 Common Stock 41,667 Direct F1, F2
transaction SANA Stock Option (Right to Buy) Award $0 +187,500 $0.000000 187,500 06 Mar 2025 Common Stock 187,500 $2.55 Direct F3
transaction SANA Restricted Stock Units Options Exercise $0 -3,250 -25% $0.000000 9,750 07 Mar 2025 Common Stock 3,250 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
F2 The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F3 The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F4 The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Remarks:

Acting Chief Financial Officer and Principal Accounting Officer